title: [Eculizumab: effectiveness of a shortened dosing schedule in the treatment of atypical haemolytic uremic syndrome of unknown origin].
authors.forename: Florence
authors.initials: F
authors.lastname: Beye
authors.forename: Charlotte
authors.initials: C
authors.lastname: Malbranche
authors.forename: Delphine
authors.initials: D
authors.lastname: Tramecon
authors.forename: Corinne
authors.initials: C
authors.lastname: Pernot
authors.forename: Gilbert
authors.initials: G
authors.lastname: Zanetta
authors.forename: Christiane
authors.initials: C
authors.lastname: Mousson
authors.forename: Marie-Hélène
authors.initials: MH
authors.lastname: Guignard
authors.forename: Aline
authors.initials: A
authors.lastname: Lazzarotti
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000627:therapeutic use*; D003404:Creatinine / Q000097:blood; D015600:Glasgow Coma Scale; D006242:Haptoglobins / Q000378:metabolism; D006454:Hemoglobins / Q000378:metabolism; D006463:Hemolytic-Uremic Syndrome / Q000188:drug therapy* / Q000209:etiology / Q000523:psychology; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008297:Male; D008875:Middle Aged; D010976:Platelet Count
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D006242:Haptoglobins; D006454:Hemoglobins; C481642:eculizumab; D003404:Creatinine; D007770:L-Lactate Dehydrogenase